Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
Diagnosis
Not yet recruiting
This trial is testing whether a new type of PET/CT scan, using a tracer that targets a protein called DLL3 found on many neuroendocrine tumor cells, can detect cancer spread more accurately than standard scans. About 200 adults with metastatic neuroendocrine tumors will receive b…
Phase: PHASE2 • Sponsor: Tingting Yuan • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC